Biologic agents for asthma are not broad-spectrum anti-inflammatory drugs. Each targets a specific cytokine or receptor within a defined inflammatory pathway. Matching the right agent to the right patient depends on correctly identifying the dominant immunological phenotype driving that patient's disease, a determination guided by three measurable biomarkers: blood eosinophil count, fractional exhaled nitric oxide, and serum total immunoglobulin E.

Approximately 50 to 60 percent of patients with severe asthma have a type 2 high (T2-high) phenotype, defined by activation of the type 2 helper T-cell (Th2) cytokine axis and innate lymphoid cell type 2 (ILC2) signaling.¹ The central cytokines of this pathway are interleukin-4 (IL-4), interleukin-5 (IL-5), and interleukin-13 (IL-13). IL-4 drives B-cell class switching to immunoglobulin E (IgE) production and promotes eosinophil recruitment. IL-5 is the principal growth factor, maturation signal, and survival factor for eosinophils, and is the primary driver of peripheral blood and airway eosinophilia. IL-13 induces goblet cell metaplasia, smooth muscle hyperresponsiveness, and subepithelial fibrosis, and directly contributes to airway hyperresponsiveness independently of eosinophil infiltration. Understanding which of these cytokines is dominant in a given patient helps select the appropriate biologic agent.

The three biomarkers used to characterize T2-high disease each reflect a distinct aspect of this pathway. Blood eosinophil count (BEC) is the most widely used and practically accessible biomarker. A BEC at or above 300 cells per microliter is the threshold most consistently associated with clinical response to anti-IL-5 agents, and counts at or above 150 cells per microliter are used as lower-boundary eligibility criteria for some agents. Fractional exhaled nitric oxide (FeNO) reflects airway eosinophilic inflammation and is produced by airway epithelial cells under the influence of IL-13 and IL-4; a FeNO at or above 25 parts per billion suggests T2-high inflammation, and values above 50 parts per billion are associated with stronger treatment responses to IL-4 (interleukin-4)/IL-13 (interleukin-13) axis blockade. Serum total IgE level is the biomarker required for omalizumab dosing, with eligible ranges defined by the prescribing label based on body weight; very high IgE values may actually fall outside the dosing table and exclude patients from omalizumab eligibility.

The T2-low phenotype encompasses patients with severe asthma whose disease does not exhibit eosinophilia, elevated FeNO, or elevated IgE. These patients may have predominantly neutrophilic airway inflammation driven by interleukin-8 (IL-8), or may have so-called paucigranulocytic disease with neither eosinophilic nor neutrophilic predominance. The mechanisms driving T2-low disease are less well characterized, and no biologic agent currently approved for asthma has demonstrated consistent efficacy in this phenotype. Recognizing T2-low disease is therefore important not only to avoid ineffective biologic prescribing but to redirect clinical attention toward comorbidity management, inhaled corticosteroid (ICS) technique optimization, and potential involvement of occupational or environmental exposures.

Within the T2-high category, overlap between the three pathways is common. A patient may have high BEC, elevated FeNO, and elevated IgE simultaneously, making multiple agents potentially eligible on biomarker grounds. In these cases, clinical factors including the predominant trigger pattern, the presence of comorbid conditions such as atopic dermatitis, chronic rhinosinusitis with nasal polyps (CRSwNP), or eosinophilic granulomatosis with polyangiitis (EGPA), and the relative magnitude of each biomarker elevation inform the final prescribing choice. Severe asthma is defined by the Global Initiative for Asthma (GINA) as asthma that requires high-dose ICS plus a second controller agent to maintain control, or that remains uncontrolled despite this regimen; biologic eligibility is restricted to this population, and confirmation of true severe disease rather than uncontrolled moderate asthma is the essential first clinical step before initiating any biologic.

Three biologic agents target the interleukin-5 (IL-5) axis that drives eosinophil production, survival, and airway recruitment: mepolizumab and reslizumab block IL-5 directly, while benralizumab targets the IL-5 receptor alpha subunit (IL-5Rα) on eosinophils and basophils. This mechanistic distinction has practical consequences for the depth and speed of eosinophil depletion achieved, and for the approved indications that extend beyond asthma for some agents.

Mepolizumab is a humanized anti-IL-5 monoclonal antibody that binds free circulating interleukin-5 (IL-5), preventing it from engaging the IL-5Rα on eosinophils. Blockade of IL-5 signaling reduces eosinophil maturation in the bone marrow, attenuates peripheral blood eosinophilia, and diminishes eosinophil survival in airway tissue. It is approved for severe eosinophilic asthma in patients aged 6 years and older, administered as a 100 mg subcutaneous injection every four weeks. The pivotal MENSA (Mepolizumab as Adjunctive Therapy in Patients with Severe Asthma) trial (Ortega 2014) enrolled patients with at least two exacerbations in the prior year and a blood eosinophil count (BEC) at or above 150 cells per microliter and demonstrated a 47 percent reduction in the annualized exacerbation rate compared with placebo, with larger reductions in the subgroup with BEC at or above 500 cells per microliter.⁶ Beyond asthma, mepolizumab is also approved for eosinophilic granulomatosis with polyangiitis (EGPA), a systemic vasculitis characterized by blood and tissue eosinophilia, and for hypereosinophilic syndrome (HES), reflecting the central role of IL-5 in sustaining eosinophilia across multiple disease contexts.

Reslizumab is also a humanized anti-IL-5 antibody but differs from mepolizumab in route and approved age range: it is administered intravenously at 3 mg per kilogram body weight every four weeks and is approved only for patients aged 18 and older. The intravenous route produces more predictable pharmacokinetics across the weight range and may achieve higher tissue concentrations than subcutaneous administration at the approved mepolizumab dose, though head-to-head comparisons are not available. Pivotal trials (Castro 2015) demonstrated approximately 50 to 59 percent reductions in exacerbation rates in patients with BEC at or above 400 cells per microliter.⁷ Reslizumab has a muscle weakness signal including rare severe cases and should be used with caution in patients with pre-existing neuromuscular disease. In practice, reslizumab is less commonly chosen than mepolizumab or benralizumab primarily because of the intravenous administration requirement.

Benralizumab targets the IL-5Rα rather than the ligand, binding directly to the alpha subunit of the IL-5 receptor on eosinophils and basophils. Receptor blockade prevents IL-5 from signaling regardless of local IL-5 concentration, but benralizumab additionally recruits natural killer (NK) cells and other effector cells via its Fc region to mediate antibody-dependent cellular cytotoxicity (ADCC) against IL-5Rα-expressing cells, producing near-complete eosinophil depletion from blood within weeks of initiation. This mechanism distinguishes benralizumab from the ligand-blocking agents and accounts for the faster and more profound eosinophil reduction it produces. Benralizumab is dosed at 30 mg subcutaneously every four weeks for the first three doses (loading phase), then every eight weeks thereafter, a reduced-frequency maintenance schedule that improves convenience relative to monthly injections. Pivotal data from the SIROCCO (Single Inhaler Triple Therapy vs. Optimised Standard Care for Patients with COPD) trial (Bleecker 2016) and CALIMA (Study to Evaluate Benralizumab in Adults and Adolescents with Inadequately Controlled Asthma) trial (FitzGerald 2016) demonstrated 51 and 36 percent reductions in annualized exacerbation rates, respectively, in patients with BEC at or above 300 cells per microliter receiving high-dose inhaled corticosteroid (ICS) plus long-acting beta-2 agonist (LABA).⁸

Selection between the three anti-IL-5 axis agents is driven by practical considerations more than by strong comparative efficacy evidence, since no large randomized trial has directly compared them head-to-head. The choice between mepolizumab and benralizumab is frequently made on the basis of injection interval preference (monthly vs. every-eight-weeks maintenance), convenience of self-administration at home for both agents, and the presence of EGPA as a comorbidity that would favor mepolizumab. Reslizumab remains the option for patients who cannot administer subcutaneous injections independently and are comfortable with clinic-based infusions, or in cases where higher per-dose exposure is pharmacokinetically desired. All three agents can produce near-complete suppression of blood eosinophilia; the clinical significance of residual tissue eosinophilia as a predictor of ongoing airway inflammation is an area of active investigation.

The availability of four biologic agents with distinct targets, dosing schedules, and approved indications creates both an opportunity for precision prescribing and a practical challenge in choosing among eligible options. A structured approach to patient selection, realistic expectations about time to response, a proactive plan for oral corticosteroid (OCS) dose reduction, and preparedness to switch agents when response is insufficient are the competencies that define effective biologic prescribing in severe asthma.

Patient selection begins with confirming severe asthma as defined by the Global Initiative for Asthma (GINA): high-dose inhaled corticosteroid (ICS) plus a second controller with or without oral corticosteroid (OCS) dependence, and persistent uncontrolled disease despite this regimen. Uncontrolled moderate asthma treated with inadequate controller therapy must be distinguished from true severe asthma before initiating biologics; optimizing ICS dose, technique, and adherence, and addressing contributing comorbidities including rhinosinusitis, gastroesophageal reflux disease (GERD), obesity, and vocal cord dysfunction, is the appropriate first step. Once true severity is confirmed, baseline biomarker measurement is mandatory: blood eosinophil count (BEC), fractional exhaled nitric oxide (FeNO), and serum total IgE. These three values, combined with the clinical profile, guide agent selection.¹¹

The first prescribing decision is whether the phenotype is allergic T2-high (elevated IgE with perennial allergen sensitization), eosinophilic T2-high (elevated BEC with or without elevated IgE), or mixed. Isolated allergic phenotype with moderate BEC and elevated IgE within the dosing table range points toward omalizumab. Dominant eosinophilic phenotype with BEC at or above 300 cells per microliter, regardless of IgE status, supports anti-IL-5 axis therapy. When BEC is elevated and FeNO is also elevated, dupilumab may be preferred because the dual interleukin-4 (IL-4) and interleukin-13 (IL-13) blockade addresses both the eosinophil survival axis (via IL-4-dependent Th2 priming) and the epithelial remodeling axis (via IL-13). In the OCS-dependent patient regardless of biomarker level, dupilumab has the strongest evidence base for OCS tapering and is generally the preferred agent in this subset. Comorbidities frequently simplify the choice: concurrent atopic dermatitis, CRSwNP, or EoE strongly favor dupilumab; concurrent eosinophilic granulomatosis with polyangiitis (EGPA) mandates mepolizumab.

The expected time to meaningful clinical response varies by agent and endpoint. Reduction in blood eosinophil count occurs within days to weeks of starting anti-IL-5 therapy and within two to four weeks with dupilumab for the allergic inflammatory markers it modulates. Symptom improvement, as measured by validated patient-reported scores such as the Asthma Control Questionnaire (ACQ) or Asthma Control Test (ACT), typically becomes evident within four to eight weeks. Reduction in exacerbation frequency, the primary endpoint in pivotal trials, is generally assessed over at least four to six months, and a minimum trial of four months is recommended before concluding insufficient response. FEV1 (forced expiratory volume in one second) improvement, when it occurs, may develop more slowly over the first year. An assessment at approximately four months should document changes in symptom scores, exacerbation rate, OCS requirement, and rescue bronchodilator use as a structured response evaluation.

OCS step-down is an explicit management goal in OCS-dependent patients initiating biologic therapy and should be planned prospectively, not deferred until the patient asks. After four to six months of biologic therapy with evidence of clinical response, OCS dose reduction can begin at a rate of approximately 10 to 20 percent every four to eight weeks, with clinical monitoring between reductions. Some patients will achieve full OCS elimination; others will reach a lower stable OCS dose. Attempting OCS reduction too rapidly risks exacerbation, so gradual tapering is preferred. Adrenal suppression from prior prolonged OCS use may be present and should be assessed before completing the taper, particularly in patients who have been on daily prednisone at doses of 10 mg or more for six months or longer.

Switching between biologic agents is appropriate when an adequate trial of the first agent fails to produce clinically meaningful improvement. The evidence base for switching is limited to observational and registry data rather than randomized trials, but available data consistently show that patients who fail one biologic can respond to an agent with a different mechanism, particularly when the second agent targets a different pathway arm. Systematic review data for anti-IL-5 agents confirm that eosinophil depletion is achieved in the great majority of treated patients, so residual exacerbations in adequately dosed patients with suppressed blood eosinophilia suggest a non-IL-5-dependent mechanism driving ongoing disease, which supports a mechanistic rationale for switching to dupilumab in that setting.¹² A practical approach is to reassess biomarkers at the time of switching: if BEC has been suppressed to near-zero by an anti-IL-5 agent but the patient continues to exacerbate, switching to dupilumab may address residual IL-13-driven airway remodeling not captured by eosinophil count alone. Conversely, if dupilumab response is insufficient and BEC remains elevated, adding or switching to an anti-IL-5 agent targeting eosinophil survival directly may add benefit. Waiting lists, prior authorization cycles, and formulary restrictions mean that practical access to a second biologic can take weeks to months, which should be communicated to patients planning a switch.

Cost and access are not peripheral considerations in biologic prescribing; they are central practical constraints. All four agents have annual wholesale acquisition costs in the range of 15,000 to 40,000 US dollars, making prior authorization from insurance payers universal and mandatory. Prior authorization typically requires documentation of the severe asthma diagnosis, failure of high-dose ICS plus long-acting beta-2 agonist (LABA), biomarker eligibility criteria, and in some cases a step-edit through omalizumab before anti-IL-5 or dupilumab will be approved. Manufacturer patient assistance programs exist for each agent and can substantially reduce or eliminate out-of-pocket cost for commercially insured patients who meet income eligibility thresholds, but navigating these programs requires dedicated administrative support. Specialty pharmacy distribution is standard for all agents; patients must be connected to a specialty pharmacy at the time of prescribing, and delays in this process frequently extend the time from prescription to first dose by two to six weeks.